

## Mouse CD229/SLAMF3 Alexa Fluor® 532-conjugated Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF2555X 100 µg

| DESCRIPTION        |   |  |  |  |  |
|--------------------|---|--|--|--|--|
| Species Reactivity | Mouse   |  |  |  |  |
| Specificity        | Detects mouse CD229/SLAMF3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 20% cross-reactivity with recombinant human CD229 is observed.                         |  |  |  |  |
| Source             | Polyclonal Goat IgG   |  |  |  |  |
| Purification       | Antigen Affinity-purified   |  |  |  |  |
| Immunogen          | Mouse myeloma cell line NS0-derived recombinant mouse CD229/SLAMF3 Lys48-Phe454 Accession # AAH95921  |  |  |  |  |
| Conjugate          | Alexa Fluor 532 Excitation Wavelength: 534 nm Emission Wavelength: 553 nm   |  |  |  |  |
| Formulation        | Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide  |  |  |  |  |
|                    | *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions. |  |  |  |  |

## **APPLICATIONS**

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

| DE | EDA | DAT | ION. | AND | STO | RAGE |
|----|-----|-----|------|-----|-----|------|
|    |     |     |      |     |     |      |

| Shipping            | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |  |  |
|---------------------|---|--|--|
| Stability & Storage | Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied                          |  |  |

## BACKGROUND

CD229, also known as T lymphocyte surface antigen Ly-9, is a type I transmembrane protein belonging to the immunoglobulin superfamily. It is also a member of the CD150/SLAM receptor family and is expressed on T and B lymphocytes. Mouse CD229 contains 2 Ig-like C2-type domains and 2 Ig-like V-type domains in its extracellular region. Two mouse alleles that differ in 6 extracellular amino acid residues have been reported. Human and mouse CD229 share 60% amino acid sequence identity in their extracellular regions.

## PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Rev. 9/12/2025 Page 1 of 1